

RECEIVED
CENTRAL FAX CENTER
JUN 20 2008



HAMRE, SCHUMANN, MUELLER & LARSON, P.C.

AN INTERNATIONAL INTELLECTUAL PROPERTY LAW FIRM

FAX TRANSMISSION June 20, 2008

TO: Mail Stop: AMENDMENT
Examiner: BERCH, Mark L
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FROM: Douglas P. Mueller

OUR REF: 11336.1003USWO

TELEPHONE: (612) 455.3800

Total pages, including cover letter: 25


PTO FAX NUMBER: 571.273.8300

If all pages are NOT received, please call us at 612.455.3800 or fax us at 612.455.3801.

Title of Document: **Amendment and Response (24 pages)**


Applicant: DATTA et al.
Serial No.: 10/540770
App. Filed: December 2, 2005
Group Art No.: 1624

Please charge any additional fees or credit overpayment to Deposit Account No. 50-3478. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: 
Name: Douglas P. Mueller
Reg. No.: 30,300

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Amy Doyle


Signature

June 20, 2008
Date

225 SOUTH SIXTH STREET • SUITE 2650 • MINNEAPOLIS • MN 55402
TEL 612.455.3800 • FAX 612.455.3801
WWW.HSML.COM • MAIL@HSML.COM

RECEIVED
CENTRAL FAX CENTER
JUN 20 2008

S/N 10/540770

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	DATTA et al.	Examiner:	BERCH, Mark L
Serial No.:	10/540770	Group Art Unit:	1624
Filed:	December 2, 2005	Docket No.:	11336.1003USWO
Title:	NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES		

CERTIFICATE UNDER 37 CFR 1.600:

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on June 20 2008.

By: Amy Doyle

Name: Amy Doyle

AMENDMENT AND RESPONSE

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Office Action of March 20, 2008, please amend the above-referenced application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Abstract begin on page 9 of this paper.

Amendments to the Claims are reflected in the listing of claims that begins on page 11 of this paper.

Remarks begin on page 22 of this paper.